a proud everyday Aussie who gave it a crack
Richard Scolyer, the Australian pathologist who helped transform melanoma from a near-certain death into a largely curable disease, died Sunday at fifty-nine — three years after defying a glioblastoma prognosis that gave him months to live. He spent those years not retreating from medicine but deepening his relationship with it, subjecting himself to experimental immunotherapy and documenting every step with a transparency that turned his own dying into a gift for future patients. His life reminds us that the most enduring scientific contributions are often inseparable from the courage of the person making them.
- A man who helped save thousands from melanoma could not ultimately save himself — glioblastoma, one of the most aggressive brain cancers known, claimed him at fifty-nine despite a remarkable three-year fight.
- Rather than accept a passive prognosis, Scolyer chose to become his own experiment, undergoing a world-first immunotherapy protocol that bought him nearly two years of active, athletic life before a recurrent tumour spread through his brain.
- His radical transparency — sharing scans, setbacks, and honest prognoses with a global online community — disrupted the silence that often surrounds terminal illness and reframed what it means to be a patient with medical expertise.
- A state funeral announced by Prime Minister Albanese signals the scale of national grief, while his family describes a hole in their lives that no tribute can fill.
- His legacy now rests on two pillars: the immunotherapy breakthroughs that continue to cure melanoma patients worldwide, and a documented cancer journey that may reshape how future patients and researchers approach incurable diagnoses.
Richard Scolyer died on Sunday at fifty-nine, three years after a glioblastoma diagnosis that doctors said would likely end his life within months. Prime Minister Anthony Albanese, who knew him as a neighbour in Sydney's inner-west, announced a state funeral and called him one of Australia's brightest lights.
Alongside Professor Georgina Long, Scolyer had already changed the meaning of melanoma — once a near-certain death sentence, now largely curable through immunotherapy, a treatment that enlists the patient's own immune system against the cancer. Thousands of lives were saved. He was a world traveller, an exceptional communicator, and a keen triathlete born in Tasmania.
When glioblastoma arrived in June 2023, Scolyer turned toward it rather than away. He became the subject of a world-first experimental treatment built on the same immunotherapy principles he had spent his career developing — a vaccine and immunotherapy administered before surgery. It was a conscious risk. For nearly two years, it worked. Then in March 2025, a recurrent tumour appeared, spreading rapidly through the left side of his brain. Surgery could not remove it entirely.
He shared all of it — the hope, the setback, the honest arithmetic of risk — with thousands of followers across many countries. He said that even if the experiment failed him personally, it would leave behind scientific knowledge to help future brain cancer patients. In an open letter written in his final days, he thanked Australians for laughing and crying with him, and expressed hope that his unguarded honesty had made the road a little easier for others facing the same darkness.
His brother-in-law described him as talented, selfless, and loyal, and said his passing had left a profound hole in the family. Scolyer's own wish for how he would be remembered was characteristically understated: a proud everyday Australian who gave it a crack, and who hoped his example might encourage others to pursue their passions with humility and love.
Richard Scolyer died on Sunday at fifty-nine, three years after being diagnosed with glioblastoma, an aggressive brain cancer that doctors said would likely kill him within six to eight months. He was the 2024 Australian of the Year, and Prime Minister Anthony Albanese announced that a state funeral would be held in his honour, describing him as a "truly remarkable man" and a "personal friend" whom he had first met as a neighbour in Sydney's inner-west.
Scolyer's name belongs to a particular kind of scientific achievement—the kind that changes what a disease means. Working with Professor Georgina Long, he transformed melanoma from a diagnosis that amounted to a death sentence into something largely curable. The mechanism was immunotherapy, a treatment that teaches a patient's own immune system to fight the cancer. Thousands of lives were saved by this work. Scolyer travelled the world sharing the research, earning a reputation as an exceptional communicator and one of the leading experts in his field.
When he was diagnosed with glioblastoma in June 2023, Scolyer faced a choice that few people in his position would have made. Rather than accept the conventional path, he decided to become the subject of his own experiment. He underwent a world-first treatment based on the very immunotherapy principles he and Long had developed for melanoma—a vaccine and immunotherapy before surgery to remove the tumour. It was a calculated risk. The treatment could have shortened his life. But Scolyer believed the potential benefits were worth it, and for nearly two years, the approach worked. He was a keen triathlete, born in Tasmania, educated at the University of Tasmania and later the University of Sydney, where he eventually became a professor.
Then in March 2025, a recurrent tumour appeared. It was growing rapidly, spreading like tree roots through the left side of his brain. A complex surgery could not remove it entirely. Scolyer shared this news with his followers—thousands of them, across many countries—with the same unflinching honesty he had brought to every update about his condition. He did not sugarcoat what was happening. He told people that the experimental treatments might have made a difference, and that the attempt had been worth the risk. "At worst," he said, "I'll leave the legacy of increased scientific knowledge to benefit future brain cancer patients."
In the days before his death, Scolyer wrote an open letter to be released by his family. He thanked Australians for their support—those he had met during his year as Australian of the Year, his online community spanning multiple countries, and his hometown in Tasmania. He acknowledged that people had laughed with him, cried with him, and encouraged him to keep going when he needed it most. He hoped that by sharing his journey without pretence, he had made the path easier for others.
His final wish for how he would be remembered was modest and precise. He wanted to be thought of as "a proud everyday Aussie who gave it a crack," someone whose example might inspire others to pursue their dreams and passions with humility, love, and compassion. On Monday, his brother-in-law Charlie Nicholl released a statement describing Scolyer as talented, passionate, selfless, and loyal. "His family meant everything to him," Nicholl said, "and his passing has left a big hole in our lives." Albanese, in his tribute, called Scolyer "one of our brightest lights and our biggest hearts." The world, he said, was a better place because of what Scolyer had contributed to it.
Citações Notáveis
Australia has lost one of our brightest lights and our biggest hearts— Prime Minister Anthony Albanese
His family meant everything to him, and his passing has left a big hole in our lives— Charlie Nicholl, Scolyer's brother-in-law
A Conversa do Hearth Outra perspectiva sobre a história
What made Scolyer's approach to his own illness different from how most scientists might have handled it?
He didn't hide behind the authority of his position. He documented everything—the fear, the hope, the setbacks—and shared it publicly. Most people in his situation would have retreated. He did the opposite.
Why did he choose to undergo an experimental treatment that could have killed him faster?
Because he believed in the science. He and Georgina Long had spent years proving that immunotherapy could work. When he got sick, he thought: why not test it on myself? If it works, I live longer. If it doesn't, at least the attempt teaches us something.
Did the treatment work?
For almost two years, yes. Then the cancer adapted. But those two years weren't wasted—they were documented, studied, shared. That's how science moves forward.
What was the cost of his public transparency?
He had to relive his diagnosis over and over, every time he posted an update. He had to be brave when he might have wanted to be private. But he chose to do it because he thought it might help someone else.
What does his legacy look like now?
Two things. First, the melanoma research—that's permanent, that's already saving lives. Second, the example he set: that a scientist can be human, can be honest about uncertainty, and can still inspire people to keep going.